Get the Stockscreener App
52.62
3.09%
-1.68
Moonlake Immunotherapeutics stock is traded at $52.62, with a volume of 852.44K.
It is down -3.09% in the last 24 hours and down -4.05% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$54.30
Open:
$53.85
24h Volume:
852.44K
Relative Volume:
1.68
Market Cap:
$3.34B
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-22.88
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
-11.47%
1M Performance:
-4.05%
6M Performance:
+33.86%
1Y Performance:
+3.10%
1-Day Range:
$52.45
$54.97
1-Week Range:
$52.45
$61.17
52-Week Range:
$31.42
$61.87
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
52.62 | 3.44B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
MoonLake Immunotherapeutics $MLTX Shares Sold by Fred Alger Management LLC - MarketBeat
Psoriasis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma - Barchart.com
Zimmer Partners LP Makes New Investment in MoonLake Immunotherapeutics $MLTX - MarketBeat
Biotech UCB’s Big Rally Has a Lot Riding on Rival’s Trial Result - SWI swissinfo.ch
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 6.9%Time to Sell? - MarketBeat
Octagon Capital Advisors LP Buys Shares of 296,000 MoonLake Immunotherapeutics $MLTX - MarketBeat
Alliancebernstein L.P. Sells 56,514 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
Granahan Investment Management LLC Has $5.56 Million Stock Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
Cubist Systematic Strategies LLC Takes Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX) - Yahoo Finance
FY2025 EPS Estimates for MLTX Decreased by Cantor Fitzgerald - MarketBeat
ADAR1 Capital Management LLC Sells 12,000 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Hits New 1-Year HighStill a Buy? - MarketBeat
Russell Investments Group Ltd. Sells 50,430 Shares of MoonLake Immunotherapeutics $MLTX - MarketBeat
Vestal Point Capital LP Acquires Shares of 200,000 MoonLake Immunotherapeutics $MLTX - MarketBeat
What’s the analyst consensus on MoonLake ImmunotherapeuticsTrade Analysis Summary & Fast Entry High Yield Tips - خودرو بانک
Forecasting MoonLake Immunotherapeutics price range with options dataRecession Risk & Daily Growth Stock Investment Tips - Newser
Using economic indicators to assess MoonLake Immunotherapeutics potentialJuly 2025 Highlights & Real-Time Market Sentiment Alerts - Newser
How to use a screener to detect MoonLake Immunotherapeutics breakoutsWatch List & Trade Opportunity Analysis - Newser
How to track smart money flows in MoonLake ImmunotherapeuticsPortfolio Gains Report & Verified High Yield Trade Plans - Newser
What institutional flow reveals about MoonLake ImmunotherapeuticsInflation Watch & Weekly Momentum Stock Picks - Newser
What MACD and RSI say about MoonLake ImmunotherapeuticsWeekly Stock Summary & Safe Entry Zone Identification - Newser
Can technical indicators confirm MoonLake Immunotherapeutics’s reversalJuly 2025 News Drivers & Consistent Growth Stock Picks - Newser
Paradigm Biocapital Advisors LP Decreases Position in MoonLake Immunotherapeutics $MLTX - MarketBeat
What are MoonLake Immunotherapeutics’s growth leversWeekly Stock Recap & Safe Entry Zone Identification - خودرو بانک
Can MoonLake Immunotherapeutics keep up with sector leaders2025 Market Outlook & Community Shared Stock Ideas - خودرو بانک
Ranking MoonLake Immunotherapeutics among high performing stocks via toolsMarket Movers & Fast Entry Momentum Trade Alerts - Newser
MoonLake Immunotherapeutics stock prediction for this week2025 Top Gainers & Fast Moving Stock Trade Plans - Newser
Can a trend reversal in MoonLake Immunotherapeutics lead to recoveryPortfolio Risk Summary & Expert Verified Stock Movement Alerts - Newser
Will MoonLake Immunotherapeutics announce a stock splitWeekly Trend Recap & Weekly High Potential Stock Alerts - خودرو بانک
Can MoonLake Immunotherapeutics rally from current levels2025 Market Sentiment & Stepwise Entry/Exit Trade Alerts - Newser
When is the best time to exit MoonLake ImmunotherapeuticsStop Loss & Daily Stock Momentum Reports - Newser
MoonLake Immunotherapeutics stock daily chart insightsIndex Update & Technical Pattern Based Buy Signals - Newser
How hedge fund analytics apply to MoonLake Immunotherapeutics stockJuly 2025 Technicals & Real-Time Volume Triggers - Newser
Will MoonLake Immunotherapeutics price bounce be sustainable2025 Trade Ideas & Real-Time Stock Price Movement Reports - Newser
Using data models to predict MoonLake Immunotherapeutics stock movementWeekly Market Outlook & Smart Investment Allocation Tips - Newser
What Technical Tools Say About MoonLake Immunotherapeutics RecoveryQuarterly Profit Review & Precise Buy Zone Identification - beatles.ru
MoonLake Immunotherapeutics stock trend outlook and recovery pathWeekly Risk Summary & Free Real-Time Market Sentiment Alerts - Newser
What recovery options are there for MoonLake ImmunotherapeuticsTreasury Yields & Fast Entry High Yield Stock Tips - Newser
What Fibonacci levels say about MoonLake Immunotherapeutics reboundTrade Exit Report & Growth Focused Entry Reports - Newser
Visual analytics tools that track MoonLake Immunotherapeutics performanceWeekly Stock Analysis & Community Verified Trade Signals - Newser
Sentiment analysis tools applied to MoonLake ImmunotherapeuticsJuly 2025 EndofMonth & Trade Opportunity Analysis Reports - Newser
How sensitive is MoonLake Immunotherapeutics to inflation2025 Price Action Summary & Growth Focused Entry Reports - خودرو بانک
MoonLake Immunotherapeutics stock hits 52-week high at 58.3 USD By Investing.com - Investing.com Australia
MoonLake Immunotherapeutics stock hits 52-week high at 58.3 USD - Investing.com
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):